SuperworthCryoport EPS CYRX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.90
- Latest quarter, Q2 FY26
- −$0.20
- −109% on a year earlier
- Fiscal year 2025
- $1.40
Cryoport's earnings per share was −$0.90 over the twelve months to Jun 30, 2026, down 164% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.20, down 109% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.40 | n/a |
| FY2024 | −$2.49 | n/a |
| FY2023 | −$2.20 | n/a |
| FY2022 | −$0.93 | n/a |
| FY2021 | −$5.93 | n/a |
| FY2020 | −$1.87 | n/a |
| FY2019 | −$0.54 | n/a |
| FY2018 | −$0.34 | n/a |
| FY2017 | −$0.35 | n/a |
| FY2016 | −$2.40 | n/a |
| FY2016 | −$0.93 | n/a |
| FY2015 | −$2.44 | n/a |
| FY2014 | −$5.52 | n/a |
| FY2013 | −$2.04 | n/a |
| FY2012 | −$3.12 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.20 | −109% | −$0.90 | |
| Q1 FY26 | −$0.25 | n/a | $1.43 | |
| Q4 FY25 | −$0.27 | n/a | $1.40 | |
| Q3 FY25 | −$0.18 | n/a | $1.25 | |
| Q2 FY25 | $2.13 | n/a | $1.41 | |
| Q1 FY25 | −$0.28 | n/a | −$2.34 | |
| Q4 FY24 | −$0.42 | n/a | −$2.49 | |
| Q3 FY24 | −$0.02 | n/a | −$3.38 | |
| Q2 FY24 | −$1.62 | n/a | −$3.67 | |
| Q1 FY24 | −$0.43 | n/a | −$2.47 | |
| Q4 FY23 | −$1.31 | n/a | −$2.20 | |
| Q3 FY23 | −$0.31 | n/a | −$1.13 |
Against its peers
Companies in Drug Manufacturers - General nearest Cryoport's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CYRXCryoport | −$0.90 | −164% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| OMEROmeros | $1.52 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| Peer median | $1.08 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cryoport
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.